Total submissions: 11
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Evidence- |
RCV000112789 | SCV000577994 | benign | Breast-ovarian cancer, familial, susceptibility to, 1 | 2017-06-29 | reviewed by expert panel | curation | Synonymous substitution variant, with low bioinformatic likelihood to alter mRNA splicing (splicing prior 0.02; http://priors.hci.utah.edu/PRIORS/) and frequency 0.0031 (East Asian), derived from ExAC (2014-12-17). |
Labcorp Genetics |
RCV001082438 | SCV000077153 | benign | Hereditary breast ovarian cancer syndrome | 2024-02-01 | criteria provided, single submitter | clinical testing | |
Ambry Genetics | RCV000163599 | SCV000214162 | likely benign | Hereditary cancer-predisposing syndrome | 2014-09-30 | criteria provided, single submitter | clinical testing | This alteration is classified as likely benign based on a combination of the following: seen in unaffected individuals, population frequency, intact protein function, lack of segregation with disease, co-occurrence, RNA analysis, in silico models, amino acid conservation, lack of disease association in case-control studies, and/or the mechanism of disease or impacted region is inconsistent with a known cause of pathogenicity. |
Cancer Genetics and Genomics Laboratory, |
RCV000496381 | SCV000586871 | likely benign | not specified | 2017-04-18 | criteria provided, single submitter | clinical testing | |
Quest Diagnostics Nichols Institute San Juan Capistrano | RCV000587508 | SCV000600437 | benign | not provided | 2022-11-25 | criteria provided, single submitter | clinical testing | |
Color Diagnostics, |
RCV000163599 | SCV000683358 | likely benign | Hereditary cancer-predisposing syndrome | 2016-02-17 | criteria provided, single submitter | clinical testing | |
Women's Health and Genetics/Laboratory Corporation of America, |
RCV000587508 | SCV000699302 | likely benign | not provided | 2017-02-21 | criteria provided, single submitter | clinical testing | Variant summary: The BRCA1 795T>C (p.Ser265Ser) variant causes a synonymous change involving the alteration of a conserved nucleotide, which 5/5 splice prediction tools predict no significant impact on normal splicing. The variant of interest was observed in the large, broad control population, ExAC, with an allele frequency of 27/121032 (1/4482), predominantly in the East Asian cohort, 27/8652 (1/320), which does exceed the estimated maximal expected allele frequency for a pathogenic BRCA1 variant of 1/1000. Therefore, suggesting the variant is a benign polymorphism found in population(s) of East Asian origin. A functional study, Raponi_2012 reports that the variant could influence the use of an alternative splice site reducing the D(11a) isoform, however, this functional experiment alone is not sufficient evidence to suggest pathogenicity. In addition, Thirthagiri_2008 and Judkins_2005, along with multiple clinical diagnostic laboratories classify the variant as "likely benign/benign/polymorphism." Taken together, this variant is classified as a "likely benign." |
Counsyl | RCV000112789 | SCV000786089 | likely benign | Breast-ovarian cancer, familial, susceptibility to, 1 | 2018-02-20 | criteria provided, single submitter | clinical testing | |
Sema4, |
RCV000163599 | SCV002537898 | likely benign | Hereditary cancer-predisposing syndrome | 2021-12-15 | criteria provided, single submitter | curation | |
Breast Cancer Information Core |
RCV000112789 | SCV000145685 | uncertain significance | Breast-ovarian cancer, familial, susceptibility to, 1 | 2010-09-18 | no assertion criteria provided | clinical testing | |
Prevention |
RCV004554692 | SCV004763714 | likely benign | BRCA1-related disorder | 2022-10-26 | no assertion criteria provided | clinical testing | This variant is classified as likely benign based on ACMG/AMP sequence variant interpretation guidelines (Richards et al. 2015 PMID: 25741868, with internal and published modifications). |